




# PHARMACEUTICAL 2020

LIXTE BIOTECHNOLOGY HOLDINGS  
INC.  
Rank 136 of 358





# PHARMACEUTICAL 2020

## LIXTE BIOTECHNOLOGY HOLDINGS INC. Rank 136 of 358

The relative strengths and weaknesses of LIXTE BIOTECHNOLOGY HOLDINGS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LIXTE BIOTECHNOLOGY HOLDINGS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 116% points. The greatest weakness of LIXTE BIOTECHNOLOGY HOLDINGS INC. is the variable Net Income, reducing the Economic Capital Ratio by 84% points.

The company's Economic Capital Ratio, given in the ranking table, is 120%, being 84% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	2,672
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	238
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	50
Other Revenues	0
Property and Equipment	0
Research and Development	821
Selling, General and Administrative Expense	1,669

Output Variable	Value in 1000 USD
Assets	2,672
Liabilities	238
Expenses	2,490
Revenues	0
Stockholders Equity	2,434
Net Income	-2,440
Comprehensive Net Income	-2,440
Economic Capital Ratio	120%